Clinical Trials on Alpha 1-Antitrypsin Deficiency

Total 356 results

Baxalta now part of Shire
Arriva Pharmaceuticals, Inc.

Completed

Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency

Alpha1-antitrypsin Deficiency

United States
Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Alpha1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland, Sweden, United Kingdom
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

Japan
Baxalta now part of Shire

Completed

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Alpha1-antitrypsin Deficiency

United States, Canada
Baxalta now part of Shire

Terminated

Aralast alpha1-proteinase Inhibitor Surveillance Study

Alpha1-antitrypsin Deficiency

United States
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

Alpha1-Antitrypsin Deficiency

Japan
Baxalta now part of Shire
Arriva Pharmaceuticals, Inc.

Completed

Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

Alpha1-antitrypsin Deficiency

United States
Baxalta now part of Shire

Completed

GLASSIA Infusion Rate Study

Healthy Volunteers | Alpha1-antitrypsin Deficiency

United States
RWTH Aachen University

Unknown

Liver Disease in Patients With alpha1-antitrypsin Deficiency

alpha1-antitrypsin Deficiency

Germany
Takeda

Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Alpha1-Antitrypsin Deficiency

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Alpha1-Antitrypsin Deficiency

United States, Belgium, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Spain, Portugal, Italy, Poland
Takeda

Enrolling by invitation

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Alpha1-Antitrypsin Deficiency

United Kingdom, Germany, United States, Austria, Portugal
Thomayer University Hospital
Masaryk University

Recruiting

Czech AATD Registry

Alpha-1-antitrypsin Deficiency

Czechia
University of Florida
Alpha-1 Foundation

Enrolling by invitation

Alpha-1 Foundation DNA and Tissue Bank

Alpha 1 Antitrypsin Deficiency

United States
Grifols Therapeutics LLC

Completed

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Alpha₁-Antitrypsin Deficiency

United States
Michael Campos, MD
CSL Behring

Completed

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

Alpha 1 Antitrypsin Deficiency

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Chronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency

United States, Canada, Australia
Shire

Withdrawn

ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study

Chronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency
Washington University School of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); N... and other collaborators

Terminated

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency (CBZ)

Liver Cirrhosis | Alpha-1-antitrypsin Deficiency

United States
Alnylam Pharmaceuticals

Terminated

A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

United Kingdom
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Genomic Research in Alpha-1 Antitrypsin Deficiency (GRADS Alpha-1)

Alpha 1 Antitrypsin Deficiency | AATD

United States
Hospices Civils de Lyon

Completed

Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort (Polygen)

Children With a Deficiency of Alpha-1 Antitrypsin

France
Heidelberg University

Terminated

Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency

Hereditary Emphysema (Alpha 1-antitrypsin Deficiency)

Germany
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency (SPARK)

Emphysema | Alpha 1-antitrypsin Deficiency (AATD)

United States
Takeda

Withdrawn

A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema

Chronic Obstructive Pulmonary Disease (COPD) | Alpha1-Antitrypsin Deficiency
Grifols Therapeutics LLC

Enrolling by invitation

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency (SPARTA-OLE)

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

United States, New Zealand, Denmark, Australia, Finland, Estonia, Canada, Poland, Russian Federation, Sweden, France
Schön Klinik Berchtesgadener Land
Grifols Therapeutics LLC; Alpha-1 Foundation

Completed

Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients

Chronic Obstructive Pulmonary Disease | Alpha-1-antitrypsin-deficiency

Germany
Permian Health Lung Institute
The Gambia Committee on Traditional Practices Affecting the Health of Women...

Not yet recruiting

Permian Health Women's Lung Health Study (WLHS)

COPD | Lung Function Decreased | Alpha 1-Antitrypsin

Gambia
Z Factor Limited
Hammersmith Medicines Research; Centessa Pharmaceuticals plc

Terminated

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects

Alpha1 Anti-Trypsin Deficiency

United Kingdom
Alnylam Pharmaceuticals

Terminated

A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Antitrypsin Deficiency Liver Disease

United Kingdom
University Hospital, Saarland

Withdrawn

Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency (LuReCAA)

Emphysema | Chronic Obstructive Lung Disease | Alpha-1-Antitrypsin Deficiency

Denmark, Germany
Rambam Health Care Campus
Hadassah Medical Organization; Tel-Aviv Sourasky Medical Center; Soroka University...

Completed

α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD (AATGVHD-MARK)

GVHD | Bone Marrow Transplant Failure | Alpha 1-Antitrypsin

Israel
Wave Life Sciences Ltd.

Recruiting

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) (RestorAATion-1)

Alpha-1 Antitrypsin Deficiency

United Kingdom
Kamada, Ltd.
Syneos Health

Recruiting

Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD (InnovAATe)

Alpha 1-Antitrypsin Deficiency

United Kingdom, Sweden, Ireland, Netherlands, Belgium, Finland
Alpha-1 Foundation

Recruiting

Alpha-1 Research Registry

Alpha 1-Antitrypsin Deficiency

United States
CSL Behring

Active, not recruiting

Respreeza® Self-administration and Learning Program (AmAREtTI Study) (AmAREtTI)

Alpha-1 Antitrypsin Deficiency

France
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Completed

Study of DCR-A1AT in Healthy Adult Volunteers

Alpha 1-Antitrypsin Deficiency

New Zealand, Sweden
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Alpha 1-Antitrypsin Deficiency

New Zealand, Australia
Baxalta now part of Shire
Baxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)

Completed

Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Alpha 1-Antitrypsin Deficiency

Australia, New Zealand
Medical University of South Carolina
Alpha-1 Foundation

Completed

Alpha-1 Foundation Research Registry

Alpha 1-Antitrypsin Deficiency

United States
National Jewish Health
Medical University of South Carolina

Unknown

Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency (AATD_Epi)

Alpha 1-Antitrypsin Deficiency

United States
Biocerna LLC

Completed

The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency

Alpha 1-Antitrypsin Deficiency

United States
Medical University of South Carolina
National Center for Research Resources (NCRR); Alpha-1 Foundation

Completed

The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency (QUANTUM-1)

Alpha-1 Antitrypsin Deficiency

United States
Grifols Therapeutics LLC

Completed

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults (ChAMP)

Alpha 1-Antitrypsin Deficiency

United States
Grifols Therapeutics LLC

Completed

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency (STAMP)

Alpha 1-Antitrypsin Deficiency

United States, United Kingdom
National Center for Research Resources (NCRR)
University of Pittsburgh

Terminated

Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency

Alpha 1-Antitrypsin Deficiency

United States
Krystal Biotech, Inc.

Recruiting

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (Serpentine-1)

Alpha 1-Antitrypsin Deficiency

United States
Hospital Universitari Vall d'Hebron Research Institute
European Respiratory Society

Recruiting

EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin (EARCO)

Alpha 1-Antitrypsin Deficiency

Spain
University of Florida

Recruiting

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study (ACT)

Alpha-1 Antitrypsin Deficiency

United States

Clinical Trials on Alpha 1-Antitrypsin Deficiency

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations